Get started
Author

Maria Marcela Monteiro

Observed names: Maria M.F. Monteiro, Maria Marcela F. Monteiro, Maria Marcela Fernandes Monteiro, Mariana R. Monteiro
OpenAlex ID: A5114093115
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
2023 · Sun Young Rha, Sun Young Rha, et al. · The Lancet Oncology · 689
Pembrolizumab in HER2-Positive Gastric Cancer
2024 · Yelena Y. Janjigian, Akihito Kawazoe, et al. · New England Journal of Medicine · 78
PDF
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study
2025 · Kohei Shitara, Sun Young Rha, et al. · Journal of Clinical Oncology · 54
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)
2021 · Dmytro Trukhin, Elena Poddubskaya, et al. · BioDrugs · 27
PDF
Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 study
2025 · Matheus de Oliveira Andrade, Isabella Gonçalves Gutierres, et al. · The Breast · 25
PDF
Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer
2024 · Renata Colombo Bonadio, Isadora Martins de Sousa, et al. · npj Breast Cancer · 10
PDF
Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study
2025 · Renata Colombo Bonadio, Monique Celeste Tavares, et al. · Breast Cancer Research and Treatment · 6
Prediction of pathologic complete response to chemoimmunotherapy in triple-negative breast cancer using tumor-infiltrating lymphocytes: Exploiting cutoff values.
2024 · ROMUALDO BARROSO-SOUSA, Isadora Martins de Sousa, et al. · Journal of Clinical Oncology · 3
PDF
Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123
2026 · Mariana Carvalho Gouveia, Romualdo Barroso-Sousa, et al. · npj Breast Cancer · 2
PDF
Real-world insights: Neoadjuvant KEYNOTE-522 regimen in triple-negative breast cancer patients with germline BRCA mutations.
2025 · Monique Celeste Tavares, Romualdo Barroso-Sousa, et al. · Journal of Clinical Oncology · 1
Role of tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer treated with KEYNOTE-522 in real-world setting
2026 · Renata Colombo Bonadio, Flávia Cavalcanti Balint, et al. · npj Breast Cancer
PDF
Differential response and survival across rare histologic subtypes of triple-negative breast cancer following neoadjuvant chemo-immunotherapy
2026 · Romualdo Barroso-Sousa, Mariana Carvalho Gouveia, et al. · npj Breast Cancer
PDF
Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: a multicenter real-world cohort
2026 · Monique Celeste Tavares, Flávia C. Balint, et al. · npj Breast Cancer
New oral SERD plus CDK4/6 inhibitors in recurrent or metastatic ER+/HER2- breast cancer: A systematic review and single-arm meta-analysis.
2026 · Lara De Holanda Jucá Silveira, Lorrany Larisse Costa Rodrigues, et al. · Journal of Clinical Oncology
Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study
2026 · Matheus de Oliveira Andrade, Renata Colombo Bonadio, et al. · Breast Cancer Research and Treatment
Abstract P5-11-30: Residual Cancer Burden (RCB) with Dose-Dense versus Every 3-Week AC regimen during Neoadjuvant Chemoimmunotherapy for Early-Stage Triple-Negative Breast Cancer – The Neo-Real Study
2025 · Renata Bonadio, Flávia Balint, et al. · Clinical Cancer Research
Abstract P2-11-14: Treatment Patterns and Safety of Adjuvant Therapy After Chemoimmunotherapy for Early-Stage Triple-Negative Breast Cancer in a Real-World Scenario: The Neo-Real Study
2025 · Renata Bonadio, Isadora Sousa, et al. · Clinical Cancer Research
Outcomes of elderly patients with early-stage triple-negative breast cancer treated with the KEYNOTE-522 regimen.
2025 · Renata Colombo Bonadio, Flavia Balint, et al. · Journal of Clinical Oncology
Pathologic response in er-low early-stage breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy
2025 · Renata Colombo Bonadio, Flávia Cavalcanti Balint, et al. · Brazilian Journal of Oncology
Abstract PO2-16-09: Dose-dense versus 3-weekly AC during Neoadjuvant Chemoimmunotherapy for Early-Stage Triple-Negative Breast Cancer (TNBC): a Real-World Safety and Efficacy Data Analysis
2024 · Renata Colombo Bonadio, Fernanda Madasi, et al. · Cancer Research
Works count: 21
Citation count: 894
H-index: 6
I10-index: 6
Year
Topic
Type